EAST HANOVER, N.J., May 24, 2019 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen1.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8524851-novartis-piqray-fda-approval-breast-cancer-treatment/

PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; approximately 40% of patients living with HR+/HER2- breast cancer have this mutation8,10. PIK3CA mutations are associated with tumor growth, resistance to endocrine treatment and a poor overall prognosis11,12. Piqray targets the effect of PIK3CA mutations and may help overcome endocrine resistance in HR+ advanced breast cancer.

"The FDA approval of Piqray, which was discovered at the Novartis Institutes for BioMedical Research, marks the first ever treatment specifically for HR+/HER2- advanced breast cancer with a PIK3CA mutation. We are proud to offer a new treatment option that specifically addresses the needs of the patients living with this mutation," said Susanne Schaffert, PhD, CEO, Novartis Oncology. "We are grateful to our researchers' bold and unrelenting pursuit of a first-in-class treatment for this incurable disease, and to the patients, investigators and administrators who participated in the clinical trials leading to this remarkable milestone."

FDA approval is based on results of the Phase III trial, SOLAR-1, that showed Piqray plus fulvestrant nearly doubled median progression-free survival (PFS) compared to fulvestrant alone in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation (median PFS 11.0 months vs 5.7 months; HR=0.65, 95% CI: 0.50-0.85; p<0.001)2. Piqray provided consistent PFS results across pre-specified subgroups, including among patients previously treated with a CDK4/6 inhibitor2,3.

Overall response rate (ORR), an indicator of the proportion of patients who experience at least a 30% reduction in overall tumor size (in patients with measurable disease), was more than doubled when Piqray was added to fulvestrant in patients with a PIK3CA mutation, (ORR= 35.7% vs 16.2% for fulvestrant alone, p=0.0002)2,3. Piqray and its associated companion diagnostic test from QIAGEN N.V. was the first combination product approved under the FDA Oncology Center of Excellence Real-Time Oncology Review pilot program. 

"Today's approval is expected to change the way we practice medicine in advanced breast cancer. For the first time, physicians can test for PIK3CA biomarkers and develop a treatment plan based on the genomic profile of a patient's cancer," said Fabrice André, MD, PhD, research director and head of INSERM Unit U981, professor in the Department of Medical Oncology at Institut Gustave Roussy in Villejuif, France, and global SOLAR-1 principal investigator. "In the SOLAR-1 Phase III trial, alpelisib plus fulvestrant nearly doubled median PFS and more than doubled overall response rate in patients with a PIK3CA mutation, offering them new hope for longer life without progression."

Patients with HR+/HER2- advanced breast cancer can be selected for treatment with Piqray based on the presence of PIK3CA mutations. Concurrent with the approval of Piqray, the therascreen®* PIK3CA companion diagnostic test from QIAGEN was also approved by the FDA and is now available for patient testing.       

"If you are facing a complex disease like metastatic breast cancer, you want to follow a path that is specific to your type of disease," said Shirley Mertz, President, Metastatic Breast Cancer Network. "Finding the right treatment team and getting the right tests, like testing for the PIK3CA mutation, will help your healthcare team identify accurate, precise treatment options for your disease."

Novartis is committed to providing patients with access to medicines, as well as resources and support to address a range of needs. The Novartis Oncology Patient Support Program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. For more information, patients and healthcare professionals can call 1-800-282-7630.

Full prescribing information for Piqray can be found at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf.

About Piqray® (alpelisib)
Piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen1.

Approximately 40% of HR+ advanced breast cancer patients have a mutation that may activate the PI3K-alpha isoform, called PIK3CA mutations5,6,7,8. These mutations are associated with resistance to endocrine therapy, disease progression and a poor prognosis11,12. Piqray works by inhibiting the PI3K pathway, predominantly the PI3K-alpha isoform, to address the effect of PIK3CA mutations.

About SOLAR-1
SOLAR-1 is a global, Phase III randomized, double-blind, placebo-controlled trial studying Piqray in combination with fulvestrant for postmenopausal women, and men, with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor1,2,3. SOLAR-1 is the pivotal Phase III trial that supported this approval.

The trial randomized 572 patients. Patients were allocated based on central tumor tissue assessment to either a PIK3CA-mutated cohort (n=341) or a PIK3CA non-mutated cohort (n=231). Within each cohort, patients were randomized in a 1:1 ratio to receive continuous oral treatment with Piqray (300 mg once daily) plus fulvestrant (500 mg every 28 days + Cycle 1 Day 15) or placebo plus fulvestrant. Stratification was based on visceral metastases and prior CDK4/6 inhibitor treatment1,2,3. Patients and investigators are blinded to PIK3CA mutation status and treatment.

The primary endpoint is local investigator assessed PFS using RECIST 1.1 for patients with a PIK3CA mutation. The key secondary endpoint is overall survival, and additional secondary endpoints include, but are not limited to, overall response rate, clinical benefit rate, health-related quality of life, efficacy in PIK3CA non-mutated cohort, safety and tolerability1,2,3. SOLAR-1 is ongoing to assess overall survival and other secondary endpoints.

About Novartis in Advanced Breast Cancer
For more than 30 years, Novartis has been tackling breast cancer with superior science, great collaboration and a passion for transforming patient care. With one of the most diverse breast cancer pipelines and one of the largest numbers of breast cancer compounds in development, Novartis leads the industry in discovery of new therapies and combinations, especially in HR+ advanced breast cancer, the most common form of the disease.

Indication
PIQRAY® (alpelisib) tablets is a prescription medicine used in combination with the medicine fulvestrant to treat women who have gone through menopause and men who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), with an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, and whose disease has progressed on or after endocrine therapy. Your health care provider will test your cancer for an abnormal "PIK3CA" gene to make sure that PIQRAY is right for you. It is not known if PIQRAY is safe and effective in children. 

Important Safety Information
Patients should not take PIQRAY if they have had a severe allergic reaction to PIQRAY or are allergic to any of the ingredients in PIQRAY. 

PIQRAY may cause serious side effects. PIQRAY can cause severe allergic reactions. Patients should tell their health care provider or get medical help right away if they have trouble breathing, flushing, rash, fever, or fast heart rate during treatment with PIQRAY. PIQRAY can cause severe skin reactions. Patients should tell their health care provider or get medical help right away if they get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, with or without fever. PIQRAY can cause high blood sugar levels (hyperglycemia). Hyperglycemia is common with PIQRAY and can be severe. Health care providers will monitor patients' blood sugar levels before they start and during treatment with PIQRAY. Health care providers may monitor patients' blood sugar levels more often if they have a history of Type 2 diabetes. Patients should tell their health care provider right away if they develop symptoms of hyperglycemia, including excessive thirst, dry mouth, urinate more often than usual or have a higher amount of urine than normal, or increased appetite with weight loss. PIQRAY can cause lung problems (pneumonitis). Patients should tell their health care provider right away if they develop new or worsening symptoms of lung problems, including shortness of breath or trouble breathing, cough, or chest pain. Diarrhea is common with PIQRAY and can be severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney problems. Patients who develop diarrhea during treatment with PIQRAY should tell their health care provider right away. 

Before taking PIQRAY, patients should tell their health care provider if they have a history of diabetes, skin rash, redness of skin, blistering of the lips, eyes or mouth, or skin peeling, are pregnant, or plan to become pregnant as PIQRAY can harm their unborn baby. Females who are able to become pregnant should use effective birth control during treatment with PIQRAY and for 1 week after the last dose. Do not breastfeed during treatment with PIQRAY and for 1 week after the last dose. Males with female partners who are able to become pregnant should use condoms and effective birth control during treatment with PIQRAY and for 1 week after the last dose. Patients should also read the Full Prescribing Information of fulvestrant for important pregnancy, contraception, infertility, and lactation information.

Patients should tell their health care provider all of the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PIQRAY and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine.

The most common side effects of PIQRAY when used with fulvestrant are rash, nausea, tiredness and weakness, decreased appetite, mouth sores, vomiting, weight loss, hair loss, and changes in certain blood tests.

Please see full Prescribing Information for Piqray, available at
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally, and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. Novartis Pharmaceuticals Corporation, a US affiliate of Novartis, is located in East Hanover, NJ. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

References

  1. Piqray (alpelisib) Prescribing Information. East Hanover., New Jersey, USA: Novartis Pharmaceuticals Corporation; May 2019.
  2. André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-Mutated, Hormone-Receptor-Positive Advanced Breast Cancer. N Eng J Med 2019.
  3. André F, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Annals of Oncology, Vol 29, Suppl 8, October 2018, Abstract LBA3_PR.
  4. Juric D, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Phase 3 SOLAR-1 trial results. Presented at the San Antonio Breast Cancer Symposium (SABCS) (Abstract #GS3-08) on December 6, 2018.
  5. Tolaney S, Toi M, Neven P, et al. Presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.
  6. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100.
  7. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730002E
  8. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
  9. Sobhani N, Roviello G, Corona SP et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292.
  10. Sabine V, Crozier C, Brookes C, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. Journal of Clinical Oncology. 2014;32:2951-2958.
  11. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and Therapeutic Implications in Breast Cancer. Breast Cancer Res. 2011.
  12. Saal LH, Johansson P, Holm K. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. PNAS. 2007;104(18):7564-7569.

*therascreen is a registered trademark of QIAGEN N.V.

SOURCE Novartis Pharmaceuticals Corporation

Read more: FDA approves Novartis Piqray® - the first and...

SILVER SPRING, Md., May 24, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

The FDA also approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients who are negative by the therascreen test using the liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing.

"Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient's specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks."

Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body (most often the bones, lungs, liver or brain). When breast cancer is hormone-receptor positive, patients may be treated with anti-hormonal treatment (also called endocrine therapy), alone or in combination with other medicines, or chemotherapy.

The efficacy of Piqray was studied in the SOLAR-1 trial, a randomized trial of 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor. Results from the trial showed the addition of Piqray to fulvestrant significantly prolonged progression- free survival (median of 11 months vs. 5.7 months) in patients whose tumors had a PIK3CA mutation.

Common side effects of Piqray are high blood sugar levels, increase in creatinine, diarrhea, rash, decrease in lymphocyte count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in lipase (enzymes released by the pancreas), decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, aPTT prolonged (blood clotting taking longer to occur than it should), and hair loss.  

Health care professionals are advised to monitor patients taking Piqray for severe hypersensitivity reactions (intolerance). Patients are warned of potentially severe skin reactions (rashes that may result in peeling and blistering of skin or mucous membranes like the lips and gums). Health care professionals are advised not to initiate treatment in patients with a history of severe skin reactions such as Stevens-Johnson Syndrome, erythema multiforme, or toxic epidermal necrolysis. Patients on Piqray have reported severe hyperglycemia (high blood sugar), and the safety of Piqray in patients with Type 1 or uncontrolled Type 2 diabetes has not been established. Before initiating treatment with Piqray, health care professionals are advised to check fasting glucose and HbA1c, and to optimize glycemic control. Patients should be monitored for pneumonitis/interstitial lung disease (inflammation of lung tissue) and diarrhea during treatment. Piqray must be dispensed with a patient Medication Guide that describes important information about the drug's uses and risks.

Piqray is the first new drug application (NDA) for a new molecular entity approved under the Real-Time Oncology Review (RTOR) pilot program, which permits the FDA to begin analyzing key efficacy and safety datasets prior to the official submission of an application, allowing the review team to begin their review and communicate with the applicant earlier. Piqray also used the updated Assessment Aid (AAid), a multidisciplinary review template intended to focus the FDA's written review on critical thinking and consistency and reduce time spent on administrative tasks. With these two pilot programs, today's approval of Piqray comes approximately three months ahead of the Prescription Drug User Fee Act (PDUFA) VI deadline of August 18, 2019.

The FDA granted this application Priority Review designation. The FDA granted approval of Piqray to Novartis. The FDA granted approval of the therascreen PIK3CA RGQ PCR Kit to QIAGEN Manchester, Ltd.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Amanda Turney, 301-796-2969, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Related Links

http://www.fda.gov

Read more: FDA approves first PI3K inhibitor for breast...

DUBLIN, May 24, 2019 /PRNewswire/ -- The "Low Voltage DC Circuit Breaker Market by End User (Battery Systems, Transportation, and Others), Application (Industrial, Commercial, and Others), Type (Air Circuit Breaker, Molded Case Circuit Breaker, and Others), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global low voltage DC circuit breaker market is projected to reach USD 1.5 billion by 2024 from an estimated USD 1.2 billion in 2019, at a CAGR of 5.68 %.

This growth can be attributed to factors such as expansion in transmission & distribution networks and upgradation & modernization of aging infrastructure for safe and secure electrical distribution systems along with the increased emphasis on the generation of electrical energy by means of renewables such as solar. However, risks associated with device malfunction and lack of existing government policies specific to low voltage DC circuit breakers are hindering the growth of the low voltage DC circuit breaker market.

The others segment is expected to be the fastest growing market from 2019 to 2024.

The others segment, by application, is estimated to be the largest as well as the fastest growing segment during the forecast period, as the dependence on electronic equipment in the residential sector has been increasing very fast that require low voltage Direct Current (DC) for their operations. With most of the existing electrical infrastructure expected to undergo a massive revamp in the near future, for instance, electricity distribution infrastructure in the US is believed to be from the world war 2 era, thus needs to be revamped. Also, in the Asia Pacific in order to incorporate the electricity generated from renewable energy sources the infrastructure needs to be revamped. All this will ensure that the low voltage dc circuit breaker installations go up.

The battery systems segment, by end-user, is expected to be the largest market from 2019 to 2024.

The battery systems segment is expected to hold the largest market share and is expected to be the fastest growing segment during the forecast period because of large scale energy storage projects coming up in the future, globally. This is bound to be supported by the ever-increasing electricity generation from renewable energy sources because of the ever-rising demand for power throughout the world. All of this is ultimately expected to drive the market during the forecast period.

The molded case circuit breaker segment, by type, is expected to be the largest market from 2019 to 2024.

The molded case circuit breaker segment is expected to hold the largest market share during the forecast period as a vast majority of low voltage DC circuit breaker applications deploy this type of circuit breaker owing to the ease of installation, reliability of operation, and low price when compared with other options. Electricity distribution substations and industries like transportation, chemical, mining, and marine are in demand for equipment operating in the low to medium voltage segment. Hence maximum low voltage DC circuit breakers lie in this voltage rating segment.

Asia Pacific: The largest market for low voltage DC circuit breakers.

The Asia Pacific region is expected to be the largest market for low voltage DC circuit breakers, by 2024. Countries such as China, Japan, and South Korea are among the major countries which are considered as the main manufacturing hubs for low voltage DC circuit breakers. Over the past few years, this region has witnessed a high rate of economic development due to a large number of manufacturing and industrial units coming up.

Also, the growth of the electricity generation from renewable energy sources in this region results in an increase in the low voltage DC circuit breaker market. The renewable energy generation in countries like China, South Korea, Japan, and India, is taking place at a rapid rate, this needs to be incorporated in the existing national grid which would need additional electrical infrastructure, thereby driving the low voltage DC circuit breaker market.

The leading players in the low voltage DC circuit breaker market are ABB (Switzerland), Eaton (US), SIEMENS AG (Germany), Shaanxi Baoguang Vacuum Electric Device Company Limited (China), and Meidensha Corporation (China).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increase in the Generation of Electricity From Renewable Energy Sources
5.2.1.2 Increasing Investments in Smart Grids to Ensure Grid Stability
5.2.1.3 Shift Toward Decentralized Power Generation & Energy Storage
5.2.2 Restraints
5.2.2.1 Inconsistencies Leading to Vulnerability Causing Operational Failures
5.2.2.2 Lack of Existing Government Policies Specific to Low Voltage DC Circuit Breakers
5.2.3 Opportunities
5.2.3.1 Development of Smart Cities & Electric Vehicles
5.2.3.2 Replacement of Old & Aging Electrical Infrastructure
5.2.3.3 Demand for Uninterrupted Power Supply From Utilities
5.2.4 Challenges
5.2.4.1 Expensive When Compared to Alternative Products
5.2.4.2 Concerns About the Cybersecurity of the Power Grid

6 Low Voltage DC Circuit Breaker Market, By Type
6.1 Introduction
6.2 By Type
6.2.1 Air Circuit Breaker
6.2.1.1 Finds Usage Mostly in Commercial Segments
6.2.2 Molded Case Circuit Breaker
6.2.2.1 Mostly Used in the Low Voltage Category
6.2.3 Others

7 Low Voltage DC Circuit Breaker Market, By Application
7.1 Introduction
7.2 By Application
7.2.1 Industrial
7.2.1.1 Increasing Automation is Likely to Drive the Market
7.2.2 Commercial
7.2.2.1 Growing Commercial Areas Globally Would Drive the Market
7.2.3 Others

8 Low Voltage DC Circuit Breaker Market, By End-User
8.1 Introduction
8.2 End-User
8.2.1 Battery System
8.2.1.1 Battery System Segment is Expected to Experience Huge Growth in Asia Pacific and North American Markets
8.2.2 Data Center
8.2.2.1 With Increasing Digitization, the Segment is Expected to Develop Massively
8.2.3 Solar
8.2.3.1 The Major Segment Driving the Renewables Market Ahead
8.2.4 Transportation
8.2.4.1 Charging Stations for Electric Vehicles are Expected to Have Massive Investments in North America and Europe
8.2.5 Others

9 Low Voltage DC Circuit Breaker Market, By Region

10 Competitive Landscape
10.1 Overview
10.2 Ranking of Players and Industry Concentration, 2017
10.3 Competitive Landscape Mapping, 2018
10.4 Competitive Scenario
10.4.1 Contracts & Agreements
10.4.2 Investments & Expansions
10.4.3 Mergers & Acquisitions
10.4.4 Others

11 Company Profiles
11.1 ABB
11.2 Eaton
11.3 Schneider Electric
11.4 Tavrida Electric
11.5 Hitachi
11.6 Fuji Electric
11.7 Powell Industries
11.8 Sensata Technologies
11.9 SIEMENS AG
11.10 C&S Electric
11.11 Hyundai Electric & Energy Systems Company
11.12 Mitsubishi Electric Corporation
11.13 Larsen & Toubro
11.14 Rockwell Automation
11.15 Entec Electric & Electronic

For more information about this report visit https://www.researchandmarkets.com/r/evncml

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Read more: Global Low Voltage DC Circuit Breaker Market...

CHARLOTTE, N.C., May 24, 2019 /PRNewswire/ -- Piedmont Natural Gas, a subsidiary of Duke Energy (NYSE: DUK), has successfully closed a $600 million debt offering – its largest debt issuance in the history of the company and its first since it merged with Duke Energy.

This transaction, which involved three disabled-veteran-owned banks as co-underwriters to sell the notes, aligns with Duke Energy's practice of routinely involving diversity-owned financial institutions in its capital raising efforts. Over the past three years, the company has worked with firms representing various backgrounds, including women-owned, African American-owned, disabled-veteran-owned and Hispanic-owned banks.

"Our focus on diversity and inclusion is unwavering – from our employees and leadership team to our suppliers, brokerage firms and investors," said Steve Young, Duke Energy's chief financial officer. "These partnerships enable us to broaden our investor base and honor veterans while also accessing low-cost capital to invest in important infrastructure for our customers."

"We are proud to be a part of this historic transaction for Piedmont Natural Gas," stated Ron Quigley, managing director at Mischler Financial, one of the disabled-veteran-owned banks participating in the transaction. "Not only does this represent another successful collaborative effort within the business community, it also carries more meaning to our firm given the timing of Memorial Day and our commitment to donate a portion of the proceeds from this transaction to causes that are important to our veteran employees."

Piedmont priced the bonds on May 21 and closed the transaction on May 24. Net proceeds will be used to retire a bank loan, repay other borrowings and other general corporate purposes.

"Everyone benefits when we bring diverse thoughts, perspectives and talents to the table," said Young. "Together, we have an opportunity to foster more innovation, enhance outreach to customers and investors and increase the business community's commitment to collaborating with a wide variety of firms."

Duke Energy

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of the largest energy holding companies in the U.S. It employs 30,000 people and has an electric generating capacity of 51,000 megawatts through its regulated utilities and 3,000 megawatts through its nonregulated Duke Energy Renewables unit.

Duke Energy is transforming its customers' experience, modernizing the energy grid, generating cleaner energy and expanding natural gas infrastructure to create a smarter energy future for the people and communities it serves. The Electric Utilities and Infrastructure unit's regulated utilities serve approximately 7.7 million retail electric customers in six states – North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky. The Gas Utilities and Infrastructure unit distributes natural gas to more than 1.6 million customers in five states – North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The Duke Energy Renewables unit operates wind and solar generation facilities across the U.S., as well as energy storage and microgrid projects.

Duke Energy was named to Fortune's 2019 "World's Most Admired Companies" list and Forbes' 2019 "America's Best Employers" list. More information about the company is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos, videos and other materials. Duke Energy's illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Contact: Catherine Butler
24-Hour: 800.559.3853

SOURCE Duke Energy

Read more: Piedmont Natural Gas completes its largest debt...

More Articles ...

Subcategories

Advertisement

Translator

Advertisement
Advertisement

SolarQuarter Tweets

Follow Us For Latest Tweets

SolarQuarter Gujarat Largest Rooftop Solar Event is Back in Ahmedabad - https://t.co/hvfKU8siIr
Monday, 20 May 2019 06:35
SolarQuarter How did India solar tenders perform in 2018-19? Here's a snapshot! solarenergy solarnews energy… https://t.co/rEDOp84n27
Wednesday, 15 May 2019 20:12
SolarQuarter Who was awarded the maximum tenders in India in 2018-19? Here's a glimpse @SolarQuarter SolarQuarter… https://t.co/jUdsZVJ5VU
Wednesday, 15 May 2019 00:29

Advertisement